Nathan Fowler
@DrNathanFowler
Followers
3K
Following
245
Media
75
Statuses
629
CMO-BostonGene; Pres-Halo House Foundation; ex Prof of Med-MD Anderson. Constantly searching for innovative ways to battle cancer and improve patients lives
Houston, TX
Joined May 2016
Beating cancer requires more than just therapy. In the middle of a campaign to double the size of Halo House. Check out our recent campaign video! https://t.co/xpMnviFg5t
0
0
1
RNA data in cancer is complex, tough to interpret, and often poorly understood. Today we published a new AI tool to help define "bad". AI is changing how we will use technology to better understand cancer. https://t.co/JK3vrg6ITS
0
0
0
Excellente presentation by Ranjit Nair @MDAndersonNews @LNastoupilMD @ChrisRFlowersMD showcasing the very promising phase 1 study results of TNB-486 in R/R FL.
1
7
23
He’s got some truly incredible content but this might be my favorite @DGlaucomflecken tweet of all time
Since the cardiac arrest, every time my kids do something sweet like climb into my lap to watch a campfire, I feel this relief that I’m still here to experience that moment. It feels happy and sad, if that makes sense. Not sure how long that feeling will last, maybe forever.
23
42
2K
In an interim analysis of the pivotal phase 2 ELARA trial, anti-CD19 #CARTcells produced a high rate of complete responses with a manageable safety profile in adults with r/r #FollicularLymphoma #lymsm #immunotherapy @DrNathanFowler @NovartisCancer
0
3
9
The #FDA has given accelerated approval to #tisagenlecleucel for treatment of adult patients with relapsed or refractory #follicular #lymphoma (#FL). Read about the #ELARA trial, published in @NatureMedicine by @DrNathanFowler that led to the approval:
oncdata.com
The FDA has granted accelerated approval of tisgenlecleucel for treatment of patients with relapsed of refractory follicular lymphoma.
0
1
6
See what our experts Drs. Fowler (@DrNathanFowler), Nancy L. Bartlett, & Patel (@KrishPatelMD) have to say about targeted, epigenetic, antibody-based, and CAR-T options in the sequential management of #FollicularLymphoma. #ASH21
https://t.co/FIAgkyMzWr
#meded #lymsm
0
3
4
Congratulations @DrNathanFowler et al on these important data. Love to see a trial vs mosun
Tisagenlecleucel in R/R #FL ELARA trial in @NatureMedicine 2+ prior lines median 4 (2-13) N=97 POD24 63% Double ref 68% CR 69% ORR 86% CRS 48.5% G≥3 0% (Lee scale) ICANS 4.1% G≥3 1% 12m PFS 67% Highly active in R/R high risk FL including refractory and POD24 pts #lymsm
0
1
5
Phenomenal. Congrats Dr Jabbour and team!
A combination of 2 targeted drugs, ponatinib+ blinatumomab, WITHOUT ANY CHEMOTHERAPY, results in 100% complete response rate, 85% complete molecular remission rate in newly diagnosed pts w/ Ph-positive #ALL. @MDAndersonNews study led by @NicholasShortMD & Jabbour #leusm #ASCO21
0
0
3
Very cool summary of our recent paper in Cancer Cell. Major impact!
0
2
11
Conserved pan-cancer microenvironment subtypes predict response to immunotherapy
cell.com
Bagaev et al. identify four tumor microenvironment (TME) subtypes that are conserved across diverse cancers and correlate with immunotherapy response in melanoma, bladder, and gastric cancers. A...
0
44
113
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
ascopubs.org
PURPOSEPhosphatidylinositol-3-kinase (PI3K) inhibitors have shown activity in relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). PI3K inhibitors have been hampered by poor long-term...
1
5
9
.@BostonGeneCorp researchers led by @DrNathanFowler found the TME subtypes act as a generalized immunotherapy biomarker across many cancer types due to the inclusion of malignant and #microenvironment components. 👉 https://t.co/ylg8kbIBta
0
2
6
Online Now: Conserved pan-cancer microenvironment subtypes predict response to immunotherapy @DrNathanFowler @BostonGeneCorp
cell.com
Bagaev et al. identify four tumor microenvironment (TME) subtypes that are conserved across diverse cancers and correlate with immunotherapy response in melanoma, bladder, and gastric cancers. A...
2
52
135
There is no "perfect biomarker" for immunotherapy prediction of response. PD-L1 & TMB are just a reference star in the universe Complexity of tumors needs complex analysis for biomarking. #NGS #transcriptomics is perhaps the answer to next-generation biomarkers 👏@DrNathanFowler
Online Now: Conserved pan-cancer microenvironment subtypes predict response to immunotherapy @DrNathanFowler @BostonGeneCorp
1
2
5
Despite a "slow" start, the class has great potential in indolent NHL.
0
0
3
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
ascopubs.org
PURPOSEPhosphatidylinositol-3-kinase (PI3K) inhibitors have shown activity in relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). PI3K inhibitors have been hampered by poor long-term...
1
5
9